CHK2 pThr383 antibody Ab
- Known as:
- CHK2 pThr383 (anti-) Antibody
- Catalog number:
- 1488052
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Acris antibodies
- Gene target:
- CHK2 pThr383 antibody
Related genes to: CHK2 pThr383 antibody Ab
- Gene:
- CHEK2 NIH gene
- Name:
- checkpoint kinase 2
- Previous symbol:
- RAD53
- Synonyms:
- CDS1, CHK2, HuCds1, PP1425, bA444G7
- Chromosome:
- 22q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-09-19
- Date modifiied:
- 2019-04-23
Related products to: CHK2 pThr383 antibody Ab
Related articles to: CHK2 pThr383 antibody Ab
- Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although vemurafenib targets the BRAFV600E mutation, its therapeutic efficacy in ATC is limited due to poor solubility and insufficient intracellular retention. In this study, vemurafenib was encapsulated in biocompatible polymeric nanocapsules (VEM-PNCs) to enable sustained intracellular delivery and evaluate its time-dependent anticancer effects. We tested the physical and chemical properties of these nanocapsules and examined their biological effects in human ATC 8305C cells. We measured cell death using MTT assays and assessed programmed cell death (apoptosis) by flow cytometry with Annexin V and Propidium Iodide, Hoechst staining, and microscopic examination. We also measured gene expression changes related to apoptosis and DNA damage using RT-qPCR. The VEM-PNCs produced a delayed onset but prolonged cytotoxic activity compared with free vemurafenib, consistent with controlled intracellular drug release rather than enhanced immediate cytotoxic potency. Empty nanocapsules showed minimal cytotoxicity. Following longer incubation periods, VEM-PNC-treated cells exhibited a higher proportion of apoptotic cells than cells treated with free vemurafenib, suggesting prolonged intracellular drug exposure. These effects were associated with up-regulation of ATM, CHEK2, and TP53, and down-regulation of MDM2 and MDM4, indicating activation of DNA damage response (DDR) and p53-associated signaling pathways. Increased expression of Caspase-3, -8, -9 and BAD suggested that both extrinsic and intrinsic apoptotic pathways were activated. Microscopic examination confirmed apoptotic features, including condensed nuclei and membrane blebbing, in cells treated with VEM-PNCs. These findings suggest that delivering vemurafenib in polymeric nanocapsules produces delayed but sustained cytotoxic and apoptotic effects in ATC cells in vitro, warranting further investigation of this nanocarrier approach for thyroid cancer treatment. Altogether, the biological results reported in this study are derived from in vitro experiments and require further validation in in vivo models. - Source: PubMed
Publication date: 2026/06/25
Heidari TaherehMotalleb GholamrezaRahdar Abbas - (Likely) pathogenic variants (pVs) in hereditary breast and/or ovarian cancer (HBOC) genes increase cancer risk, but the clinical implications of multiple pVs remain insufficiently understood. - Source: PubMed
Publication date: 2026/06/11
Herold NatalieEngel ChristophSpeiser DorotheeRipperger TimGehrig AndreaHarbeck NadiaArnold NorbertDikow NicolaLedig SusanneLeinert ElenaRath MatthiasHauke JanMorlot SusanneDitsch NinaRitter JuliaBlümcke BrittaSchröder JörgWaha AnkeHester AnnaMaringa MonikaJäger Bernadette A SSchmutzler RitaWimberger PaulineWappenschmidt BarbaraSander BjoernSolbach ChristineWeber Bernhard H FBlaum TobiasSchroeder ChristopherVolk Alexander EAktas BahriyeKiechle MarionMeisel CorneliaFehm TanjaHahnen EricAuber BerndRhiem KerstinGolas Monika M - The objective of the study was to evaluate the prevalence of pathogenic variants in 18 cancer predisposition genes in a national cohort of women with breast cancer diagnosed at age 40 or younger. - Source: PubMed
Publication date: 2026/06/23
Metcalfe KellyNarod Steven APoll AlettaHoey ChristianneWarner EllenBaxter Nancy NIsherwood SusanMacDougall EllenZemani NedaYang FloraSuwito Jason SamuelQuan May-LynnAkbari Mohammad R - Multiple myeloma (MM) is characterized by genomic instability and therapeutic resistance. Emerging evidence indicates that germline DNA damage response (DDR) mutations, including BRCA1/2, ATM, and CHEK2 variants, contribute to MM susceptibility, clonal evolution, and treatment response. Inherited DDR defects promote chromosomal instability, reshape the immune microenvironment, and facilitate therapy-driven disease progression. Recent advances in multiomics profiling, single-cell sequencing, and liquid biopsy have improved the functional interpretation and clinical monitoring of DDR alterations. Moreover, DDR-associated vulnerabilities provide opportunities for precision therapies, including PARP inhibitor-based synthetic lethality strategies. This review summarizes the mechanistic and clinical significance of germline DDR alterations in MM and highlights their translational potential in precision oncology. - Source: PubMed
Publication date: 2026/06/17
Shen QianWang YingCai LiuhuanQian Juan - Hereditary cancer genetic testing has been routinely recommended for individuals whose personal or family history meets the National Comprehensive Cancer Network® (NCCN®) guidelines. Midstate Radiology Associates (MRA) implemented universal risk screening in 2021 using the Ambry CARE Program®. This digital tool collects personal and family history, applies NCCN® guidelines, and identifies patients meeting criteria for hereditary breast, ovarian, pancreatic, prostate cancer, Lynch syndrome, and familial adenomatous polyposis. However, many individuals fall outside these guidelines or have limited knowledge of their family history. To address this gap, all patients were offered genetic testing regardless of guideline eligibility. This study analyzes four years of data from 15 MRA sites throughout Connecticut, where all were offered hereditary cancer genetic testing after risk assessment. - Source: PubMed
Cooke JennaBurgess Meghan EFecteau Heather